Diabetic foot ulcer medication decision assisting method and system and storage medium
By collecting images of patients' wounds and data on their physical condition, and using image recognition and large language models for evaluation, the treatment milestones for diabetic foot ulcers are dynamically determined. This allows for the matching of traditional Chinese medicine drug combinations, solving the problem of inaccurate timing of medication in the treatment of diabetic foot ulcers. It also achieves standardization and individualization of TCM external treatment plans, thereby improving treatment outcomes.
Patent Information
- Application Number
- CN202511045602.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-29
- Publication Date
- 2025-10-31
AI Technical Summary
In the current technology, the treatment of diabetic foot ulcers relies on the physician's experience, which leads to inaccurate judgment of the timing of medication, affecting the treatment effect, and there is a lack of standardized and individualized TCM external treatment plans.
By collecting images of patients' wounds and data on their physical condition, and using image recognition models and large language models for evaluation, the system dynamically identifies the transition points between "eliminating pathogens and clearing heat" and "removing blood stasis and promoting new tissue growth," and matches appropriate traditional Chinese medicine drug combinations to provide precise medication decisions.
It has enabled precise assessment and treatment strategy transformation of diabetic foot ulcer wounds, provided standardized and individualized TCM external treatment plans, improved treatment effects, and reduced reliance on physician experience.
Smart Images
Figure CN120878036A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of smart medical technology, and in particular to a decision-making assistance method and system for medication of diabetic foot ulcers, as well as a storage medium. Background Technology
[0002] Diabetic foot ulcers are one of the most common and serious complications of diabetes, and a significant factor in disability and death among diabetic patients. The incidence of foot ulcers among diabetic patients in my country is approximately 2%, and is showing a year-on-year increasing trend. Worldwide, approximately 50% of amputations each year are due to diabetic foot ulcers, placing a heavy disease burden on patients.
[0003] Diabetic foot ulcers are a complication of poorly controlled diabetes, involving vascular and neuropathy, accompanied by lower limb tissue damage, ulcer formation, and limb infection, requiring timely and effective treatment. However, conventional Western medicine treatments are not ideal. This disease falls under the category of "gangrene" in Traditional Chinese Medicine and is related to dampness, heat toxins, and excessive fire toxins in the patient, leading to meridian stagnation and resulting in flesh necrosis and tendon decay.
[0004] Based on the principles of traditional Chinese medicine (TCM) syndrome differentiation, TCM external therapies have accumulated advantages in the clinical management of local wounds in diabetic foot ulcers and can become one of the preferred intervention methods in clinical practice. However, the key to treating diabetic foot ulcers lies in dynamic syndrome differentiation, that is, accurately identifying the transition point in the ulcer wound from "eliminating pathogenic factors and clearing heat" to "removing blood stasis and promoting tissue regeneration." Otherwise, if the timing of medication is incorrect, the treatment effect will be greatly reduced, or even the optimal treatment opportunity will be missed. Currently, the judgment of this transition point usually relies on the physician's clinical experience, therefore the treatment effect varies from person to person. Summary of the Invention
[0005] Therefore, the main objective of this invention is to provide a method and system for assisting in medication decisions for diabetic foot ulcers, as well as a storage medium, to dynamically identify the transition points of "eliminating pathogens and clearing heat" and "removing blood stasis and promoting new tissue growth" in individual diabetic foot ulcers, thereby providing accurate auxiliary decisions for medication.
[0006] To achieve the above objectives, according to one aspect of the present invention, a method for assisting decision-making regarding medication for diabetic foot ulcers is provided, comprising the steps of:
[0007] Images of the patient's wounds are collected and processed by an image recognition model to obtain wound recognition information;
[0008] Collect patient physical condition data and wound condition evaluation data, process them using a large language model, and obtain patient indicator evaluations;
[0009] Based on preset evaluation weights, wound identification information and indicator evaluation are assigned values and combined into a status value.
[0010] Based on the threshold of the transition node, the node where the state value is located is determined so as to dynamically match the corresponding Chinese medicine drug composition and output the medication decision.
[0011] In a possible preferred embodiment, the physical condition data includes at least one of fasting venous blood glucose, two-hour postprandial blood glucose, and glycated hemoglobin data.
[0012] In a possible preferred embodiment, the wound condition evaluation data includes: DMIST data, Wagner data, ABI data, VEGF data of the wound, and skin temperature of the wound.
[0013] In a possible preferred embodiment, the evaluation of the index includes:
[0014] Feature A: Whether the body's blood sugar level is too high;
[0015] Feature B: Whether the DMIST score is less than 9 points or has decreased by 2 points or more compared to before treatment;
[0016] Feature C: Wagner rating results;
[0017] Feature D: Whether the VEGF parameter exceeds 1.5 times the level at the start of treatment;
[0018] Feature E: Whether the ABI parameter has increased compared to pre-treatment levels or is between 0.9 and 1.3;
[0019] Feature F: Whether the skin temperature of the wound exceeds the standard.
[0020] In a possible preferred embodiment, the step of assigning values to wound identification information and indicator evaluations according to preset evaluation weights, and merging them into a state value, includes:
[0021] The evaluation value for feature A is 0 if yes and 1 if no.
[0022] The evaluation value for feature B is 0 if yes and 2 if no.
[0023] The C rating is assigned as follows: 0 for level 0 to 1, 1 for level 2, 2 for level 3, and 3 for level 4 and above.
[0024] The evaluation value for feature D is 0 if yes and 1 if no.
[0025] The evaluation value for the assigned feature E is 0 if yes and 1 if no.
[0026] The evaluation value of the assigned feature F is 0 if yes and 1 if no;
[0027] When the wound identification information contains any of the following symptoms, assign a value of 1 and accumulate the result:
[0028] Localized redness / swelling, oozing and seeping from the wound, unclear pus and necrotic tissue, tenderness to the touch, and unpalatable flesh color;
[0029] The cumulative values of features A through F and wound identification information are used as state values.
[0030] In a possible preferred embodiment, the step of determining the node where the state value is located based on the transition node threshold includes:
[0031] Let the threshold value of the transition node be the median of the total weight values;
[0032] When the state value is less than the median value, the node is determined to be at the stage of removing blood stasis and promoting new blood production.
[0033] When the state value is greater than the median value, the node is determined to be in the stage of clearing heat and eliminating pathogens.
[0034] In a possible preferred embodiment, the matched traditional Chinese medicine composition comprises:
[0035] When the body is in the stage of dispelling pathogens and clearing heat, the matching Chinese medicine composition is composed of the following active ingredients in parts by weight: 9 parts of Phellodendron bark, 9 parts of Atractylodes lancea rhizome, and 12 parts of Achyranthes bidentata root.
[0036] In a possible preferred embodiment, the matched traditional Chinese medicine composition comprises:
[0037] When the body is in the stage of removing blood stasis and promoting new blood production, the matching Chinese medicine composition has the following active ingredients in parts by weight: 3.5 parts cinnabar, 1.5 parts gromwell root, 2.5 parts donkey-hide gelatin, 0.5 parts borneol, 3 parts dragon's blood, and 1.5 parts astragalus.
[0038] In a possible preferred embodiment, the medication decision includes: a traditional Chinese medicine composition formula for clearing heat and eliminating pathogens and its preparation method, and a method for external application of medication to the wound.
[0039] In a possible preferred embodiment, the medication decision includes: a traditional Chinese medicine composition formula corresponding to the blood stasis removal and tissue regeneration node and its preparation method, and a method for external application of medication to the wound.
[0040] To achieve the above objectives, according to another aspect of the present invention, a decision support system for medication of diabetic foot ulcers is also provided, comprising:
[0041] The storage unit contains programs that implement the steps of the decision support method for medication of diabetic foot ulcers as described above, so that the communication unit, image recognition unit, analysis unit, evaluation unit and processing unit can retrieve and execute them as needed.
[0042] The communication unit is used to collect images of the patient's wound, physical condition data, and wound condition evaluation data.
[0043] The image recognition unit is used to process images of patient wounds and obtain wound recognition information.
[0044] The analysis unit is used to process patient physical status data and wound status evaluation data through a large language model to obtain patient indicator evaluations.
[0045] The evaluation unit is used to assign values to wound identification information and indicator evaluation according to preset evaluation weights, and to combine and statistically analyze them into a status value;
[0046] The processing unit is used to determine the node where the state value is located based on the transition node threshold, so as to dynamically match the corresponding traditional Chinese medicine drug composition and output the medication decision.
[0047] To achieve the above objectives, according to another aspect of the present invention, a computer-readable storage medium is also provided, on which a computer program is stored, wherein the computer program, when executed by a processor, implements the steps of the method as described in any one of the above.
[0048] This invention, through its method, system, and storage medium for assisting in medication decisions for diabetic foot ulcers, innovatively integrates image recognition and large language model recognition technologies. This assists physicians in dynamically, flexibly, and accurately assessing the transition point of diabetic foot ulcer wounds from "eliminating pathogenic factors and clearing heat" to "removing blood stasis and promoting tissue regeneration" within massive amounts of patient data, and provides targeted and accurate medication decisions. This solution successfully constructs a standardized clinical assessment tool for multi-phase therapy of diabetic foot ulcers (DFU). By integrating inflammation control, tissue repair, and traditional Chinese medicine (TCM) disease identification indicators, it achieves accurate prediction of treatment strategy transformation, providing crucial support for the standardization and individualized implementation of TCM external treatment plans. This solution effectively overcomes the limitations of traditional medication strategies that overly rely on physician experience, and to some extent compensates for the shortage of experienced physicians in existing hospitals, providing a favorable guarantee for improving patient treatment outcomes. Attached Figure Description
[0049] The accompanying drawings, which form part of this application, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an undue limitation of the invention. In the drawings:
[0050] Figure 1 This is a schematic diagram of the steps in the decision-making assistance method for diabetic foot ulcer medication of the present invention;
[0051] Figure 2 This is a schematic diagram of the decision support system for diabetic foot ulcer medication of the present invention. Detailed Implementation
[0052] To enable those skilled in the art to better understand the technical solutions of the present invention, the specific technical solutions of the present invention will be clearly and completely described below in conjunction with embodiments, so as to help those skilled in the art further understand the present invention. Obviously, the embodiments described in this application are merely some embodiments of the present invention, and not all embodiments. It should be noted that, for those skilled in the art, the embodiments and features in the embodiments of this application can be combined with each other without departing from the concept of the present invention and without conflict. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort should fall within the disclosure and protection scope of the present invention.
[0053] Furthermore, the terms "first," "second," "S100," "S200," etc., used in the specification, claims, and drawings of this invention are used to distinguish similar objects and are not necessarily used to describe a specific order or sequence. It should be understood that such features can be interchanged where appropriate so that embodiments of the invention described herein can be implemented in orders other than those described herein. At the same time, the stages described in each step are not necessarily to be implemented in the same step; it should be understood that the implementation order of the contents of each step stage can be adjusted and interchanged without violating the inventive concept, so that embodiments of the invention described herein can be implemented in orders other than those described herein. Additionally, the terms "comprising" and "having," and any variations thereof, are intended to cover non-exclusive inclusion. Unless otherwise expressly specified and limited, the terms "set," "arrange," "install," "connect," and "link" should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral connection; a mechanical connection or an electrical connection; a direct connection or an indirect connection through an intermediate medium; or a connection within two elements. Those skilled in the art can understand the specific meaning of the above terms in this case based on the specific circumstances and in conjunction with existing technology.
[0054] In order to provide accurate auxiliary decision-making for medication by dynamically identifying the transition points of "eliminating pathogens and clearing heat" and "removing blood stasis and promoting new tissue growth" in individual diabetic foot ulcers, such as... Figure 1 As shown, the present invention provides a decision-making assistance method for medication of diabetic foot ulcers, the example steps of which include:
[0055] Step S1: Collect images of the patient's wound, process them using an image recognition model, and obtain wound recognition information.
[0056] Specifically, referring to the "Quality Control Standard for Diabetic Foot Ulcers" approved by the Shanghai Science and Technology Commission and the diagnostic criteria for non-ischemic diabetic foot in relevant literature, the necessary conditions for determining diabetic foot ulcers are:
[0057] There is no history of intermittent claudication in the affected limb, nor is there any rest pain. The affected foot is not pale or cyanotic, and the skin temperature is normal or near normal (temperature difference <1℃ compared to the healthy side) or even higher than the healthy side. The posterior tibial artery, anterior tibial artery, and dorsalis pedis artery pulses are present, or weakened or absent, but the elevation pallor test is negative.
[0058] Based on experience, a diagnosis can be made if two or more of the following characteristics are present:
[0059] (1) Characteristics of wet gangrene and / or mixed gangrene. (2) Localized swelling of the affected foot: such as single or multiple localized swellings of the flexor tendons of the toes, dorsum of the foot, palm, heel, and ankle. (3) Abnormal swelling of the affected area, presenting as macrodactyly or macrometas, with solid swelling and high tension. (4) In the later stage of swelling, an inflammatory reaction occurs, with redness and burning, and skin lesions appear in the central part, with oozing bloody secretions, often accompanied by a putrid odor. (5) Single cavity ulcers or multiple perforating ulcers are formed on the palm, dorsum of the foot, toes, or ankle. (6) Different degrees of tendon degeneration can be seen in the deep necrotic tissue: the tendons lose their luster and turn grayish-white, with reduced elasticity and thickened edema. (7) Systemic symptoms of poisoning such as high fever, nausea, and vomiting may occur.
[0060] Excluding non-wound symptoms such as high fever, vomiting, and poisoning, after a diagnosis of diabetic foot ulcer symptoms, the wound of a typical patient mainly contains the characteristics of categories 1-6 mentioned above. Therefore, based on the physician's observation experience, this example collects the corresponding wound images and labels them as: local redness or swelling, oozing and seepage of the wound, unclear pus and necrosis, tenderness of the wound, and unremarkable flesh color, etc., to pre-train the image recognition model (such as YOLO11). After completion, the wound recognition information containing the aforementioned labels is obtained based on the input patient wound image.
[0061] Step S2 collects patient physical condition data and wound condition evaluation data, processes them using a large language model, and obtains patient indicator evaluations.
[0062] In this example, the physical condition data includes at least one of the following: fasting venous blood glucose, 2-hour postprandial blood glucose, and glycated hemoglobin data, to evaluate whether the body's blood glucose level is normal. Examples of wound condition evaluation data include: DMIST data, Wagner data, ABI data, VEGF data of the wound, and wound skin temperature, to evaluate the wound condition from multiple dimensions.
[0063] Specifically, to accurately assess the transition point from "eliminating pathogens and clearing heat" to "removing blood stasis and promoting new tissue growth" in diabetic foot ulcer wounds, the experiment used 79 patients as the clinical evaluation tool group. Whether the treatment strategy transition occurred between the median number of days from the start of treatment was considered the outcome variable. Clinical evaluation indicators at the time of transition were used as independent variables. The indicators obtained from univariate analysis (P<0.200) were further incorporated into multivariate logistic regression analysis. For indicators with statistically significant differences (P<0.05), their partial regression coefficients (β values) were used to establish regression equations and build a discriminant model for the clinical evaluation tool. Receiver operating characteristic (ROC) curves were plotted, and the specific values of each clinical evaluation indicator corresponding to the optimal cutoff value were identified. The area under the ROC curve (AUC), sensitivity, specificity, and Youden's index were recorded to construct the clinical evaluation tool.
[0064] Validation of the clinical evaluation tool: Another 79 patients were used as the validation group. The values of various indicators corresponding to the transformation of the "eliminating pathogens and clearing heat - removing blood stasis and promoting new tissue growth" treatment strategy were recorded. The sensitivity, specificity, overall concordance rate, diagnostic consistency coefficient, and Bland-Altman test of the tool were calculated based on the discriminant equation to validate the clinical evaluation tool. A p-value < 0.05 was considered statistically significant.
[0065] Meanwhile, 15 authoritative experts in the field of traditional Chinese medicine surgery were invited for consultation, representing 10 different institutions. 14 experts (93.33%) held senior professional titles, and 13 (86.67%) held master's degrees or higher. Their average years of work experience was 22.13 ± 6.14 years. The expert authority coefficient was 0.85. The Kendall coefficient for expert opinion reconciliation was 0.327 in the first round of consultation and 0.544 in the second round, indicating that the experts' opinions tended to be consistent after two rounds of consultation, and no further round of consultation was conducted.
[0066] The results of the first round of consultations revealed that several indicators, including blood lipid levels (mean 4.10), wound area measurement (CV 33.33%), IL-6 (maximum score frequency 6.67%), wound edge clarity (CV 40.00%), subjective pain (CV 31.91%), and general weakness (mean 3.90), did not meet the cutoff criteria and were removed after thorough discussion by the project team. After the second round of consultations, all indicators showed a mean ≥ 5.90, CV ≤ 16.67%, and maximum score frequency ≥ 53.33%, with expert consensus indicating no further removal of indicators. Finally, a standardized clinical assessment tool for multi-phase therapy was developed.
[0067] Table 1 Expert Consultation Status Table
[0068]
[0069] Clinical patient treatment status:
[0070] A total of 158 patients were included in the clinical study for the construction and validation of standardized clinical assessment tools for multiphase therapy. The modeling group consisted of 79 patients with a mean age of 62.41 ± 8.71 years and 45 males (57.96%). The validation group consisted of 79 patients with a mean age of 61.98 ± 9.20 years and 43 males (54.43%). There were no statistically significant differences in age and sex between the two groups (P > 0.05).
[0071] There were no statistically significant differences between the two groups in terms of enrollment clinical indicators, median treatment phase transition time, and overall efficacy (P > 0.05). See Table 2 for details.
[0072] Table 2: Comparison of TCM indicators, median transition time, and efficacy between the two groups of patients before and after treatment.
[0073]
[0074] Using 79 patients as the evaluation tool, a univariate analysis was conducted on whether the treatment strategy shift occurred at the median number of days between the start of treatment and the commencement of the "eliminating pathogens and clearing heat - removing blood stasis and promoting new tissue growth" treatment strategy. The analysis revealed statistically significant differences in indicators such as fasting venous blood glucose (mmol / L) (P < 0.05). Further analysis of factors with P < 0.2 in a logistic regression model showed that indicators such as fasting venous blood glucose, Wagner classification, DMIST score, ABI data, and VEGF data influenced whether patients shifted their treatment strategy at the median number of days (P < 0.05).
[0075] Among them, the skin temperature at the wound site is one of the main criteria for judging the condition of the wound. Since it cannot be judged directly through image recognition technology, it is classified as the final data of wound condition evaluation in this example, and the evaluation is preferably carried out by actual measurement.
[0076] The standardized assessment tool established above can accurately determine the patient's transition point after analyzing the various validated data. Therefore, based on the above logical judgment process, a large language model is trained using the above data to analyze and summarize patient characteristic expressions, and then output the patient indicator evaluation required for subsequent judgment, including:
[0077] Feature A: Whether the body's blood sugar level is too high (e.g., whether the blood sugar level 2 hours after a meal exceeds 10.0 mmol / L).
[0078] Feature B: Whether the DMIST score is less than 9 points or has decreased by 2 points or more compared to before treatment;
[0079] Feature C: Wagner rating results;
[0080] Feature D: Whether the VEGF parameter exceeds 1.5 times the level at the start of treatment;
[0081] Feature E: Whether the ABI parameter has increased compared to pre-treatment levels or is between 0.9 and 1.3;
[0082] Feature F: Whether the skin temperature of the wound exceeds the standard.
[0083] Step S3 assigns values to wound identification information and indicator evaluation according to preset evaluation weights, and combines them into a status value.
[0084] Specifically, this example uses a total weight of 14 points to assign values to wound identification information and indicator evaluation. The example judgment is as follows:
[0085] 1) Whether the body's blood sugar level is above the standard (e.g., whether the blood sugar level 2 hours after a meal exceeds 10.0 mmol / L), 0 points for yes, 1 point for no;
[0086] 2) Diabetic foot DMIST scale score <9 or a decrease of 2 or more points from before treatment: 0 points if yes, 2 points if no;
[0087] 3) Diabetic foot Wagner rating: 0-1 grade, 1 point for grade 2; 2 points for grade 3; 3 points for grade 4 and above;
[0088] 4) If the expression of vascular endothelial growth factor (VEGF) in the diabetic foot wound exceeds 1.5 times that at the start of treatment, 0 points are awarded if yes and 1 point if no.
[0089] 5) If the ankle-brachial index (ABI) is higher than before treatment or between 0.9 and 1.3, 0 points are awarded if the ABI is higher than before treatment, and 1 point is awarded if the ABI is lower than before treatment.
[0090] 5) Is the skin temperature of the wound abnormally high? Yes, 0 points; no, 1 point.
[0091] 6) The score for disappearance or improvement of symptoms of local syndrome differentiation in diabetes in traditional Chinese medicine (local redness or swelling, oozing and seepage of sores, unclear pus and necrosis, tenderness of sores, and unpalatable flesh color) is 0 points, and 1 point is awarded for each item that does not improve.
[0092] The values of features 1 to 6 are accumulated and used as state values.
[0093] Step S4 determines the node where the state value is located based on the transition node threshold, so as to dynamically match the corresponding traditional Chinese medicine drug composition and output the medication decision.
[0094] Specifically, taking a total score of 14 points as an example, if a patient's score is less than 7 points, it indicates that the TCM treatment should shift from "eliminating pathogens and clearing heat" to "removing blood stasis and promoting new blood production." If the score is greater than 7 points, it is determined that the patient is still in the stage of eliminating pathogens and clearing heat.
[0095] Furthermore, when determining the corresponding node of dispelling pathogens and clearing heat, the preferred matching Chinese medicine composition in this example has the following active ingredients composed of the following parts by weight: 9 parts of Phellodendron bark, 9 parts of Atractylodes lancea rhizome, and 12 parts of Achyranthes bidentata root.
[0096] In addition, in optional embodiments, the output medication decision may include, in addition to the traditional Chinese medicine composition, a method for preparing the traditional Chinese medicine composition and a method for external application to the wound, to guide drug preparation and patient treatment. The preparation method of the traditional Chinese medicine composition for the "eliminating pathogens and clearing heat" stage includes the following steps: adding 100ml of water and decocting, reducing the decoction to 50ml, cooling to room temperature, and storing at -20℃ for later use.
[0097] When treating wounds externally, the method of application includes: applying a single layer of gauze soaked in the aforementioned decoction, the size of which should be slightly larger than the wound surface, covering it with eight layers of dry sterile gauze, and securing it with adhesive tape.
[0098] Furthermore, when corresponding to the node of removing blood stasis and promoting new blood production, the matching Chinese medicine composition has the following active ingredients in parts by weight: 3.5 parts cinnabar, 1.5 parts gromwell root, 2.5 parts donkey-hide gelatin, 0.5 parts borneol, 3 parts dragon's blood, and 1.5 parts astragalus.
[0099] In addition, in optional embodiments, the output medication decision may include, in addition to the traditional Chinese medicine composition, a method for preparing the traditional Chinese medicine composition and a method for external application of the medication to the wound, so as to guide the preparation of the medication and the external treatment of the patient. The preparation method of the traditional Chinese medicine composition for the "removing blood stasis and promoting new tissue growth" stage includes the following steps: weigh the traditional Chinese medicine composition as described above, soak it in water for 30 minutes, decoct it twice for 1.5 hours each time, combine the decoctions at 80°C, filter it, concentrate the filtrate to a clear paste with a relative density of 1.20-1.25, cool it to 40°C, add ethanol to make the alcohol content reach 75%, stir it thoroughly, let it stand for 12 hours, take the supernatant, add an appropriate amount of 75% ethanol to the residue, stir it evenly, let it stand for 12 hours, filter it, combine the two filtrates, recover the ethanol until there is no alcohol taste, add an appropriate amount of white dextrin and purified water to adjust the relative density to about 1.1, spray dry it, add an appropriate amount of microcrystalline cellulose and sodium carboxymethyl starch to the spray-dried fine powder, mix it evenly, make it into granules, and use white petrolatum, lanolin and other excipients to adjust the composition to a paste state.
[0100] When treating wounds externally, the medication application method includes: applying the ointment evenly to the gauze, applying two layers of gauze with the ointment to the wound with appropriate pressure, covering with dry gauze, and bandaging with moderate pressure.
[0101] Through the above examples, this invention achieves accurate prediction of the transformation of treatment strategies from "eliminating pathogens and clearing heat" to "removing blood stasis and promoting new tissue growth," providing important support for the standardization and individualized implementation of TCM external treatment plans. This plan can effectively replace the judgment of senior physicians and provide patients with reliable medication strategies.
[0102] On the other hand, corresponding to the above methods, such as Figure 2 As shown, the present invention also provides a decision support system for medication use in diabetic foot ulcers, comprising:
[0103] The storage unit contains programs that implement the steps of the decision support method for medication of diabetic foot ulcers as described above, so that the communication unit, image recognition unit, analysis unit, evaluation unit and processing unit can retrieve and execute them as needed.
[0104] The communication unit is used to collect images of the patient's wound, physical condition data, and wound condition evaluation data.
[0105] The image recognition unit is used to process images of patient wounds and obtain wound recognition information.
[0106] The analysis unit is used to process patient physical status data and wound status evaluation data through a large language model to obtain patient indicator evaluations.
[0107] The evaluation unit is used to assign values to wound identification information and indicator evaluation according to preset evaluation weights, and to combine and statistically analyze them into a status value;
[0108] The processing unit is used to determine the node where the state value is located based on the transition node threshold, so as to dynamically match the corresponding traditional Chinese medicine drug composition and output the medication decision.
[0109] On the other hand, corresponding to the above methods, the present invention also provides a computer-readable storage medium having a computer program stored thereon, wherein the computer program, when executed by a processor, implements the steps of any of the methods described above.
[0110] In summary, the method, system, and storage medium for assisting diabetic foot ulcer medication decisions of this invention innovatively integrate image recognition and large language model recognition technologies. This assists physicians in dynamically, flexibly, and accurately assessing the transition point of diabetic foot ulcer wounds from "clearing heat and eliminating pathogens" to "removing blood stasis and promoting tissue regeneration" from massive amounts of patient data, and provides targeted and accurate medication decisions. This solution successfully constructs a standardized clinical assessment tool for multi-phase therapy of diabetic foot ulcers (DFU). By integrating inflammation control, tissue repair, and TCM disease identification indicators, it achieves accurate prediction of treatment strategy transformation, providing important support for the standardization and individualized implementation of TCM external treatment plans. This solution can effectively overcome the limitations of traditional medication strategies that rely excessively on physician experience, and to a certain extent compensates for the shortage of experienced physicians in existing hospitals, providing a favorable guarantee for improving patient treatment outcomes.
[0111] The preferred embodiments of the present invention disclosed above are merely illustrative of the invention. These preferred embodiments do not exhaustively describe all details, nor do they limit the invention to the specific implementations described. Clearly, many modifications and variations can be made based on the content of this specification. This specification selects and specifically describes these embodiments to better explain the principles and practical applications of the invention, thereby enabling those skilled in the art to better understand and utilize the invention. The present invention is limited only by the claims and their full scope and equivalents. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the invention should be included within the protection scope of the invention.
[0112] Those skilled in the art will understand that, besides implementing the system, apparatus, unit, and its modules provided by this invention in purely computer-readable program code, the same program can be implemented in the form of logic gates, switches, application-specific integrated circuits, programmable logic controllers, and embedded microcontrollers by logically programming the method steps. Therefore, the system, apparatus, and its modules provided by this invention can be considered a hardware component, and the modules included therein for implementing various programs can also be considered structures within the hardware component; alternatively, modules for implementing various functions can be considered both software programs implementing the method and structures within the hardware component.
[0113] Furthermore, all or part of the steps in the methods of the above embodiments can be implemented by a program instructing related hardware. This program is stored in a storage medium and includes several instructions to cause a microcontroller, chip, or processor to execute all or part of the steps of the methods described in the various embodiments of this application. The aforementioned storage medium includes various media capable of storing program code, such as a USB flash drive, a portable hard drive, a read-only memory (ROM), a random access memory (RAM), a magnetic disk, or an optical disk.
[0114] Furthermore, various different implementations of the present invention can be combined arbitrarily, as long as they do not violate the spirit of the present invention, they should also be regarded as the content disclosed in the present invention.
Claims
1. A decision-making aid method for medication in diabetic foot ulcers, comprising the following steps: Images of the patient's wounds are collected and processed by an image recognition model to obtain wound recognition information; Collect patient physical condition data and wound condition evaluation data, process them using a large language model, and obtain patient indicator evaluations; Based on preset evaluation weights, wound identification information and indicator evaluation are assigned values and combined into a status value. Based on the threshold of the transition node, the node where the state value is located is determined so as to dynamically match the corresponding Chinese medicine drug composition and output the medication decision.
2. The decision-making assistance method for diabetic foot ulcer medication according to claim 1, wherein the body status data includes: At least one of the following: fasting venous blood glucose, 2-hour postprandial blood glucose, and glycated hemoglobin data.
3. The decision-making assistance method for medication in diabetic foot ulcers according to claim 2, wherein the wound status evaluation data includes: DMIST data, Wagner data, ABI data, VEGF data of wound vascular endothelial growth factor, and skin temperature of the wound in diabetic foot.
4. The decision-making assistance method for diabetic foot ulcer medication according to claim 3, wherein the evaluation of the indicators includes: Feature A: Whether the body's blood sugar level is too high; Feature B: Whether the DMIST score is less than 9 points or has decreased by 2 points or more compared to before treatment; Feature C: Wagner rating results; Feature D: Whether the VEGF parameter exceeds 1.5 times the level at the start of treatment; Feature E: Whether the ABI parameter has increased compared to pre-treatment levels or is between 0.9 and 1.3; Feature F: Whether the skin temperature of the wound exceeds the standard.
5. The decision-making assistance method for medication in diabetic foot ulcers according to claim 4, wherein the step of assigning values to wound identification information and indicator evaluation according to preset evaluation weights, and merging and statistically analyzing them into a state value, includes: The evaluation value for feature A is 0 if yes and 1 if no. The evaluation value for feature B is 0 if yes and 2 if no. The C rating is assigned as follows: 0 for level 0 to 1, 1 for level 2, 2 for level 3, and 3 for level 4 and above. The evaluation value for feature D is 0 if yes and 1 if no. The evaluation value for the assigned feature E is 0 if yes and 1 if no. The evaluation value of the assigned feature F is 0 if yes and 1 if no; When the wound identification information contains any of the following symptoms, assign a value of 1 and accumulate the result: Localized redness / swelling, oozing and seeping from the wound, unclear pus and necrotic tissue, tenderness to the touch, and unpalatable flesh color; The cumulative values of features A through F and wound identification information are used as state values.
6. The decision-making assistance method for diabetic foot ulcer medication according to claim 1, wherein the step of determining the node where the state value is located based on the transition node threshold includes: Let the threshold value of the transition node be the median of the total weight values; When the state value is less than the median value, the node is determined to be at the stage of removing blood stasis and promoting new blood production. When the state value is greater than the median value, the node is determined to be in the stage of clearing heat and eliminating pathogens.
7. The decision-making assistance method for diabetic foot ulcer medication according to claim 6, wherein the matched traditional Chinese medicine composition comprises: When the body is in the stage of dispelling pathogens and clearing heat, the matching Chinese medicine composition is composed of the following active ingredients in parts by weight: 9 parts of Phellodendron bark, 9 parts of Atractylodes lancea rhizome, and 12 parts of Achyranthes bidentata root.
8. The decision-making assistance method for diabetic foot ulcer medication according to claim 6, wherein the matched traditional Chinese medicine composition comprises: When the body is in the stage of removing blood stasis and promoting new blood production, the matching Chinese medicine composition has the following active ingredients in parts by weight: 3.5 parts cinnabar, 1.5 parts gromwell root, 2.5 parts donkey-hide gelatin, 0.5 parts borneol, 3 parts dragon's blood, and 1.5 parts astragalus.
9. The method for assisting decision-making in the treatment of diabetic foot ulcers according to claim 7, wherein the medication decision includes: The prescriptions and preparation methods of traditional Chinese medicine compositions corresponding to the points of clearing heat and eliminating pathogens, as well as the methods of external application of medicines to wounds.
10. The method for assisting medication decisions for diabetic foot ulcers according to claim 8, wherein the medication decision includes: The traditional Chinese medicine drug composition formulas and their preparation methods for the nodes of removing blood stasis and promoting new blood production, as well as the methods of external application of drugs to wounds.
11. A decision support system for medication in diabetic foot ulcers, comprising: The storage unit contains a program that implements the steps of the decision-making assistance method for medication of diabetic foot ulcers as described in any one of claims 1 to 10, for the communication unit, image recognition unit, analysis unit, evaluation unit and processing unit to retrieve and execute as needed. The communication unit is used to collect images of the patient's wound, physical condition data, and wound condition evaluation data. The image recognition unit is used to process images of patient wounds and obtain wound recognition information. The analysis unit is used to process patient physical status data and wound status evaluation data through a large language model to obtain patient indicator evaluations. The evaluation unit is used to assign values to wound identification information and indicator evaluation according to preset evaluation weights, and to combine and statistically analyze them into a status value; The processing unit is used to determine the node where the state value is located based on the transition node threshold, so as to dynamically match the corresponding traditional Chinese medicine drug composition and output the medication decision.
12. A computer-readable storage medium having a computer program stored thereon, wherein, When the computer program is executed by a processor, it implements the steps of the method according to any one of claims 1 to 10.